Roche said its Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said on Wednesday. ZURICH, Oct 13 (Reuters) - Roche ROG.S said its Ocrevus ...
“For people with MS, maintaining mobility for as long as possible is very important. We are encouraged by these new longer-term analyses showing that earlier initiation of Ocrevus treatment may reduce ...
– 35% reduction in risk of needing a walking aid in relapsing multiple sclerosis (RMS) after 7.5 years vs. initiation 2 years later in Phase III open-label extension (OLE) – – 29% reduction in 48-week ...
NEW YORK, June 2 (Reuters) - Acorda Therapeutics Inc. on Monday said it will seek U.S. approval early next year for the first medicine to improve walking for patients with multiple sclerosis, lifting ...
An online tool developed to facilitate efficient patient-provider decisions on disease modifying drugs for multiple sclerosis (MS) ran into several challenges and warrants further study. Researchers ...
– Post-hoc analysis from 6 years of Phase III open-label extension studies showed Ocrevus treatment reduced the risk of needing a walking aid (EDSS≥6) by 49% in relapsing multiple sclerosis (RMS) ...
ZURICH, Oct 13 (Reuters) - Roche (ROG.S), opens new tab said its Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said on Wednesday. There was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results